Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

医学 克里唑蒂尼 临床终点 ROS1型 肺癌 肿瘤科 内科学 临床试验 癌症 胃肠病学 外科 腺癌 恶性胸腔积液
作者
Alice T. Shaw,Benjamin Solomon,Rita Chiari,Gregory J. Riely,Benjamin Besse,Ross A. Soo,Steven Kao,Chia‐Chi Lin,Todd M. Bauer,Jill S. Clancy,Holger Thurm,Jean‐François Martini,Gerson Peltz,Antonello Abbattista,Sherry Li,Sai‐Hong Ignatius Ou
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:20 (12): 1691-1701 被引量:357
标识
DOI:10.1016/s1470-2045(19)30655-2
摘要

Background Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most known resistance mutations in ALK and ROS1. We investigated the antitumour activity and safety of lorlatinib in advanced, ROS1-positive non-small-cell lung cancer (NSCLC). Methods In this open-label, single-arm, phase 1–2 trial, we enrolled patients (aged ≥18 years) with histologically or cytologically confirmed advanced ROS1-positive NSCLC, with or without CNS metastases, with an Eastern Cooperative Oncology Group performance status of 2 or less (≤1 for phase 1 only) from 28 hospitals in 12 countries worldwide. Lorlatinib 100 mg once daily (escalating doses of 10 mg once daily to 100 mg twice daily in phase 1 only) was given orally in continuous 21-day cycles until investigator-determined disease progression, unacceptable toxicity, withdrawal of consent, or death. The primary endpoint was overall and intracranial tumour response, assessed by independent central review. Activity endpoints were assessed in patients who received at least one dose of lorlatinib. This study is ongoing and is registered with ClinicalTrials.gov, NCT01970865. Findings Between Jan 22, 2014, and Oct 2, 2016, we assessed 364 patients, of whom 69 with ROS1-positive NSCLC were enrolled. 21 (30%) of 69 patients were TKI-naive, 40 (58%) had previously received crizotinib as their only TKI, and eight (12%) had previously received one non-crizotinib ROS1 TKI or two or more ROS1 TKIs. The estimated median duration of follow-up for response was 21·1 months (IQR 15·2–30·3). 13 (62%; 95% CI 38–82) of 21 TKI-naive patients and 14 (35%; 21–52) of 40 patients previously treated with crizotinib as their only TKI had an objective response. Intracranial responses were achieved in seven (64%; 95% CI 31–89) of 11 TKI-naive patients and 12 (50%; 29–71) of 24 previous crizotinib-only patients. The most common grade 3–4 treatment-related adverse events were hypertriglyceridaemia (13 [19%] of 69 patients) and hypercholesterolaemia (ten [14%]). Serious treatment-related adverse events occurred in five (7%) of 69 patients. No treatment-related deaths were reported. Interpretation Lorlatinib showed clinical activity in patients with advanced ROS1-positive NSCLC, including those with CNS metastases and those previously treated with crizotinib. Because crizotinib-refractory patients have few treatment options, lorlatinib could represent an important next-line targeted agent. Funding Pfizer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一一发布了新的文献求助10
1秒前
molihuakai的应助被开心德地采纳,获得10
1秒前
汉堡包的应助被超级无敌采纳,获得10
1秒前
1秒前
杨涵完成签到 ,获得积分10
2秒前
ding的应助被小迷鹿采纳,获得10
2秒前
纾寒发布了新的文献求助10
2秒前
kalani发布了新的文献求助10
3秒前
jqy发布了新的文献求助10
3秒前
4秒前
何肥肥发布了新的文献求助10
4秒前
4秒前
4秒前
FAN完成签到 ,获得积分10
5秒前
ku发布了新的文献求助10
5秒前
CodeCraft的应助被开心德地采纳,获得10
5秒前
MAX发布了新的文献求助10
6秒前
小绵羊完成签到,获得积分10
6秒前
无物发布了新的文献求助100
7秒前
下午茶完成签到 ,获得积分10
7秒前
LIUDAN发布了新的文献求助10
7秒前
Orange的应助被费马福尔摩斯采纳,获得10
7秒前
qwertyuiop完成签到,获得积分10
7秒前
辣椒酱拌泡面完成签到,获得积分10
7秒前
加了醋的豆浆完成签到,获得积分10
7秒前
8秒前
三眼乌鸦完成签到,获得积分10
8秒前
吴旭完成签到,获得积分10
8秒前
Search瞬间发布了新的文献求助10
8秒前
霜双双发布了新的文献求助10
8秒前
shuyiWang发布了新的文献求助10
9秒前
斯文败类的应助被开心德地采纳,获得10
9秒前
西红柿完成签到,获得积分10
10秒前
10秒前
12秒前
超级无敌发布了新的文献求助10
12秒前
脑洞疼的应助被开心德地采纳,获得10
12秒前
RONG完成签到,获得积分10
13秒前
6哈完成签到,获得积分10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189302
求助须知:如何正确求助?哪些是违规求助? 9576666
关于积分的说明 21849295
捐赠科研通 7787245
什么是DOI,文献DOI怎么找? 3435521
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509